FLT3 and acute myeloid leukemia: Building on these results, the ongoing phase III trial NCT03258931 is comparing crenolanib plus standard chemotherapy with midostaurin plus chemotherapy in newly diagnosed FLT3-mutated AML, with overall survival as the primary endpoint [78].